Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions.

Nicolas JM, Bouzom F, Hugues C, Ungell AL.

Biopharm Drug Dispos. 2017 Apr;38(3):209-230. doi: 10.1002/bdd.2052. Epub 2017 Feb 6. Review.

2.

Gut Wall Metabolism. Application of Pre-Clinical Models for the Prediction of Human Drug Absorption and First-Pass Elimination.

Jones CR, Hatley OJ, Ungell AL, Hilgendorf C, Peters SA, Rostami-Hodjegan A.

AAPS J. 2016 May;18(3):589-604. doi: 10.1208/s12248-016-9889-y. Epub 2016 Mar 10. Review.

3.

Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models.

Peters SA, Jones CR, Ungell AL, Hatley OJ.

Clin Pharmacokinet. 2016 Jun;55(6):673-96. doi: 10.1007/s40262-015-0351-6. Review.

4.

Prediction of fraction metabolized via CYP3A in humans utilizing cryopreserved human hepatocytes from a set of 12 single donors.

Desbans C, Hilgendorf C, Lutz M, Bachellier P, Zacharias T, Weber JC, Dolgos H, Richert L, Ungell AL.

Xenobiotica. 2014 Jan;44(1):17-27. doi: 10.3109/00498254.2013.809617. Epub 2013 Jul 24.

PMID:
23883428
5.

Comprehensive study on regional human intestinal permeability and prediction of fraction absorbed of drugs using the Ussing chamber technique.

Sjöberg Å, Lutz M, Tannergren C, Wingolf C, Borde A, Ungell AL.

Eur J Pharm Sci. 2013 Jan 23;48(1-2):166-80. doi: 10.1016/j.ejps.2012.10.007. Epub 2012 Oct 26.

PMID:
23103351
6.

Characterization of THLE-cytochrome P450 (P450) cell lines: gene expression background and relationship to P450-enzyme activity.

Soltanpour Y, Hilgendorf C, Ahlström MM, Foster AJ, Kenna JG, Petersen A, Ungell AL.

Drug Metab Dispos. 2012 Nov;40(11):2054-8. doi: 10.1124/dmd.112.045815. Epub 2012 Jul 30.

PMID:
22851615
7.

Impact of input parameters on the prediction of hepatic plasma clearance using the well-stirred model.

Wan H, Bold P, Larsson LO, Ulander J, Peters S, Löfberg B, Ungell AL, Någård M, Llinàs A.

Curr Drug Metab. 2010 Sep;11(7):583-94.

PMID:
20629632
8.

The Effects of Pregnenolone 16α-Carbonitrile Dosing on Digoxin Pharmacokinetics and Intestinal Absorption in the Rat.

Lowes S, Haslam IS, Fihn BM, Hilgendorf C, Karlsson JE, Simmons NL, Ungell AL.

Pharmaceutics. 2010 Mar 15;2(1):61-77.

9.

Paracellular porosity and pore size of the human intestinal epithelium in tissue and cell culture models.

Linnankoski J, Mäkelä J, Palmgren J, Mauriala T, Vedin C, Ungell AL, Lazorova L, Artursson P, Urtti A, Yliperttula M.

J Pharm Sci. 2010 Apr;99(4):2166-75. doi: 10.1002/jps.21961.

PMID:
19827099
10.

Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization.

Peters SA, Ungell AL, Dolgos H.

Curr Opin Drug Discov Devel. 2009 Jul;12(4):509-18. Review.

PMID:
19562647
11.

In vitro and in silico identification and characterization of thiabendazole as a mechanism-based inhibitor of CYP1A2 and simulation of possible pharmacokinetic drug-drug interactions.

Thelingwani RS, Zvada SP, Dolgos H, Ungell AL, Masimirembwa CM.

Drug Metab Dispos. 2009 Jun;37(6):1286-94. doi: 10.1124/dmd.108.024604. Epub 2009 Mar 19.

PMID:
19299526
12.

Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories.

Hayeshi R, Hilgendorf C, Artursson P, Augustijns P, Brodin B, Dehertogh P, Fisher K, Fossati L, Hovenkamp E, Korjamo T, Masungi C, Maubon N, Mols R, Müllertz A, Mönkkönen J, O'Driscoll C, Oppers-Tiemissen HM, Ragnarsson EG, Rooseboom M, Ungell AL.

Eur J Pharm Sci. 2008 Dec 18;35(5):383-96. doi: 10.1016/j.ejps.2008.08.004. Epub 2008 Aug 19.

PMID:
18782614
13.

Lysosomal trapping of amodiaquine: impact on transport across intestinal epithelia models.

Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL.

Biopharm Drug Dispos. 2008 Sep;29(6):324-34. doi: 10.1002/bdd.616.

PMID:
18570280
14.

Induction of metabolism and transport in human intestine: validation of precision-cut slices as a tool to study induction of drug metabolism in human intestine in vitro.

van de Kerkhof EG, de Graaf IA, Ungell AL, Groothuis GM.

Drug Metab Dispos. 2008 Mar;36(3):604-13. Epub 2007 Dec 19.

PMID:
18094037
15.

Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines.

Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karlsson J.

Drug Metab Dispos. 2007 Aug;35(8):1333-40. Epub 2007 May 11.

PMID:
17496207
16.

Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies.

Sköld C, Winiwarter S, Wernevik J, Bergström F, Engström L, Allen R, Box K, Comer J, Mole J, Hallberg A, Lennernäs H, Lundstedt T, Ungell AL, Karlén A.

J Med Chem. 2006 Nov 16;49(23):6660-71.

PMID:
17154497
17.

Innovative methods to study human intestinal drug metabolism in vitro: precision-cut slices compared with ussing chamber preparations.

van de Kerkhof EG, Ungell AL, Sjöberg AK, de Jager MH, Hilgendorf C, de Graaf IA, Groothuis GM.

Drug Metab Dispos. 2006 Nov;34(11):1893-902. Epub 2006 Aug 16.

PMID:
16914511
18.

The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux.

Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL.

Eur J Pharm Sci. 2006 Sep;29(1):70-81. Epub 2006 Jun 3.

PMID:
16846720
19.

Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells.

Seithel A, Karlsson J, Hilgendorf C, Björquist A, Ungell AL.

Eur J Pharm Sci. 2006 Jul;28(4):291-9. Epub 2006 Mar 22.

PMID:
16704924
20.

Impact of extracellular protein binding on passive and active drug transport across Caco-2 cells.

Neuhoff S, Artursson P, Zamora I, Ungell AL.

Pharm Res. 2006 Feb;23(2):350-9. Epub 2006 Jan 1.

PMID:
16388407
21.

Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2.

Lindahl A, Sjöberg A, Bredberg U, Toreson H, Ungell AL, Lennernäs H.

Mol Pharm. 2004 Sep-Oct;1(5):347-56.

PMID:
16026004
22.

pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers.

Neuhoff S, Ungell AL, Zamora I, Artursson P.

Eur J Pharm Sci. 2005 Jun;25(2-3):211-20. Epub 2005 Mar 23.

PMID:
15911216
23.

Caco-2 replace or refine?

Ungell AL.

Drug Discov Today Technol. 2004 Dec;1(4):423-30. doi: 10.1016/j.ddtec.2004.11.003.

PMID:
24981623
24.
25.

Surface descriptors for protein-ligand affinity prediction.

Zamora I, Oprea T, Cruciani G, Pastor M, Ungell AL.

J Med Chem. 2003 Jan 2;46(1):25-33.

PMID:
12502357
26.

Pharmacokinetically based mapping device for chemical space navigation.

Oprea TI, Zamora I, Ungell AL.

J Comb Chem. 2002 Jul-Aug;4(4):258-66.

PMID:
12099842
27.

Influence of hydrodynamics and particle size on the absorption of felodipine in labradors.

Scholz A, Abrahamsson B, Diebold SM, Kostewicz E, Polentarutti BI, Ungell AL, Dressman JB.

Pharm Res. 2002 Jan;19(1):42-6.

PMID:
11837699
29.

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.

Gustafsson D, Nyström J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sörensen H, Någård S, Abrahamsson A, Bylund R.

Thromb Res. 2001 Feb 1;101(3):171-81.

PMID:
11228340
30.

Paracellular drug transport across intestinal epithelia: influence of charge and induced water flux.

Karlsson J, Ungell A, Gråsjö J, Artursson P.

Eur J Pharm Sci. 1999 Oct;9(1):47-56.

PMID:
10493996
31.

Evaluation of viability of excised rat intestinal segments in the Ussing chamber: investigation of morphology, electrical parameters, and permeability characteristics.

Polentarutti BI, Peterson AL, Sjöberg AK, Anderberg EK, Utter LM, Ungell AL.

Pharm Res. 1999 Mar;16(3):446-54.

PMID:
10213378
32.

Surface activity and concentration dependent intestinal permeability in the rat.

Lindahl A, Persson B, Ungell AL, Lennernäs H.

Pharm Res. 1999 Jan;16(1):97-102.

PMID:
9950286
34.

Evaluation of dynamic polar molecular surface area as predictor of drug absorption: comparison with other computational and experimental predictors.

Palm K, Luthman K, Ungell AL, Strandlund G, Beigi F, Lundahl P, Artursson P.

J Med Chem. 1998 Dec 31;41(27):5382-92.

PMID:
9876108
35.

Concentration- and region-dependent intestinal permeability of fluvastatin in the rat.

Lindahl A, Sandström R, Ungell AL, Lennernäs H.

J Pharm Pharmacol. 1998 Jul;50(7):737-44.

PMID:
9720622
36.

Membrane transport of drugs in different regions of the intestinal tract of the rat.

Ungell AL, Nylander S, Bergstrand S, Sjöberg A, Lennernäs H.

J Pharm Sci. 1998 Mar;87(3):360-6.

PMID:
9523990
37.

Is the jejunal permeability in rats age-dependent?

Lindahl A, Krondahl E, Grudén AC, Ungell AL, Lennernäs H.

Pharm Res. 1997 Sep;14(9):1278-81. No abstract available.

PMID:
9327463
38.

Jejunal permeability: a comparison between the ussing chamber technique and the single-pass perfusion in humans.

Lennernäs H, Nylander S, Ungell AL.

Pharm Res. 1997 May;14(5):667-71. No abstract available.

PMID:
9165541
39.

Characterization of fluids from the stomach and proximal jejunum in men and women.

Lindahl A, Ungell AL, Knutson L, Lennernäs H.

Pharm Res. 1997 Apr;14(4):497-502.

PMID:
9144738
40.

Jejunal permeability and hepatic extraction of fluvastatin in humans.

Lindahl A, Sandström R, Ungell AL, Abrahamsson B, Knutson TW, Knutson L, Lennernäs H.

Clin Pharmacol Ther. 1996 Nov;60(5):493-503.

PMID:
8941022
41.

Correlation of drug absorption with molecular surface properties.

Palm K, Luthman K, Ungell AL, Strandlund G, Artursson P.

J Pharm Sci. 1996 Jan;85(1):32-9.

PMID:
8926580
42.
44.

Effects of enzymatic inhibition and increased paracellular shunting on transport of vasopressin analogues in the rat.

Ungell AL, Andreasson A, Lundin K, Utter L.

J Pharm Sci. 1992 Jul;81(7):640-5.

PMID:
1403696
45.
46.

The fate of noradrenaline and adrenaline in the perfused cod spleen.

Ungell AL.

Fish Physiol Biochem. 1989 May;6(3):157-65. doi: 10.1007/BF01874772.

PMID:
24227071
47.

Chloride-dependence of the potency of inhibitors of the neuronal noradrenaline carrier in the rat vas deferens.

Ungell AL, Oberleithner H, Graefe KH.

Naunyn Schmiedebergs Arch Pharmacol. 1989 Jan-Feb;339(1-2):65-70.

PMID:
2725700
48.

Total body, systemic and pulmonary clearance and fractional extraction of unlabelled and differently 3H-labelled noradrenaline in the anaesthetized rabbit.

Halbrügge T, Ungell AL, Wölfel R, Graefe KH.

Naunyn Schmiedebergs Arch Pharmacol. 1988 Oct;338(4):361-7.

PMID:
3244381
49.

Study on adrenergic function after development of tolerance to ethylene glycol dinitrate (EGDN) in rats.

Johansson P, Ehrenström F, Ungell AL.

Pharmacol Toxicol. 1987 Sep;61(3):172-81.

PMID:
3684949
50.

Failure of K+ to affect the potency of inhibitors of the neuronal noradrenaline carrier in the rat vas deferens.

Ungell AL, Graefe KH.

Naunyn Schmiedebergs Arch Pharmacol. 1987 Mar;335(3):250-4.

PMID:
3587371

Supplemental Content

Loading ...
Support Center